Briakinumab

Summary

Briakinumab (CHEMBL1742995) is a phase-3 clinical-stage antibody (ATC L04AC09); indicated across 4 conditions including immune system disorder and psoriasis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• ATC class: L04AC09
• Indications: 4 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1742995
Name	Briakinumab
Type	Antibody
Max phase	3
ATC	L04AC09

Also known as: A-796874.0, ABT-874, Briakinumab, BSF 415977, BSF-415977, J-695, J695, LU 415977, LU-415977, Ozespa, WAY-165772, BRIAKINUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
immune system disorder	3	MONDO:0005046	EFO:0000540
psoriasis	3	MONDO:0005083	EFO:0000676
Crohn disease	2	MONDO:0005011	EFO:0000384
multiple sclerosis	2	MONDO:0005301	MONDO:0005301

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE3	5
PHASE2	3
PHASE1	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00570986	PHASE3	COMPLETED	A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00626002	PHASE3	COMPLETED	Open Label Continuation Study in Moderate to Severe Psoriasis
NCT00679731	PHASE3	COMPLETED	A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
NCT00691964	PHASE3	COMPLETED	Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00710580	PHASE3	COMPLETED	Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00086671	PHASE2	COMPLETED	Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)
NCT00292396	PHASE2	COMPLETED	Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00562887	PHASE2	TERMINATED	Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn’s Disease
NCT00007163	PHASE1	COMPLETED	Monoclonal Antibody Treatment of Crohn’s Disease
NCT00870948	PHASE1	COMPLETED	Phase 1 BA Study, Single Center With Healthy Volunteers
NCT01260844	PHASE1	WITHDRAWN	Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).